Treatment Effectiveness
User reported effectiveness ratings NuvaRing for various conditions.
| Conditions | Major Improvement | Moderate Improvement | Much Worse | No Effect | Worse | Responses |
|---|---|---|---|---|---|---|
| Endometriosis | 5% | 20% | 25% | 25% | 25% | 40 |
| Polycystic Ovary Syndrome (PCOS) | 0% | 75% | 0% | 25% | 0% | 4 |
| Vulvodynia | 0% | 10% | 37% | 40% | 13% | 30 |
Side Effects
User-reported side effects of NuvaRing
| Side Effect | Percent of Reports NuvaRing |
|---|---|
| Nervousness | 6% |
| Acne | 25% |
| Breasts That Are Large, Tender, or Produce a Liquid | 25% |
| Changes in Appetite | 38% |
| Growth of Hair on Face | 7% |
| Loss of Hair on Scalp | 6% |
| Runny Nose | 13% |
| Seizures | 6% |
| Stomach Cramps or Bloating | 25% |
| Swelling, Redness, Irritation, Burning, Itching, or Infection of the Vagina | 25% |
| Vaginal Bleeding or Spotting When It Is Not Time for Your Period. (Call Your Doctor if the Bleeding | 41% |
| Vomiting | 6% |
| Weight Gain or Loss | 25% |
| White or Yellow Vaginal Discharge | 31% |
| Headache | 44% |
| Nausea | 38% |
| Changes in Sexual Desire | 33% |
Outcomes
Below is the degree of change seen after NuvaRing is higher than average.
|
|
Outcomes Label
NuvaRing Info
| Property | Value |
|---|---|
| Variable Name | NuvaRing |
| Aggregation Method | SUM |
| Analysis Performed At | 2020-04-07 |
| Duration of Action | 21 days |
| Filling Value | 0 |
| Minimum Allowed Value | 0 count |
| Number of Aggregate Predictors | 0 |
| Number of Aggregate Outcomes | 0 |
| Number of Measurements | 0 |
| Number of Measurements (including those generated by tagged, joined, or child variables) | 0 |
| Public | true |
| Onset Delay | 30 minutes |
| Unit | Count |
| User Variables | 0 |
| Variable Category | Treatments |
| Variable ID | 94649 |